Life sciences lead local patent requests [p.15]

May 15, 2006 02:08


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The life sciences industry continued to lead the way in Israeli innovation and research, accounting for 50 percent of all patent requests submitted in 2005. A survey conducted by the life sciences division of Reinhold Cohn attorneys showed that of a total of 6,842 patent requests presented last year, approximately half were in the biotechnology, medical devices and pharmaceutical industries, which make up the life sciences sector. "In the last few years there has been a strong rise in patent activity in life sciences," said Ilan Cohn, senior partner at Reinhold Cohn. "The high level of activity in the local industry is without doubt also apparent in the area of patents." According to the survey, one-quarter of the total life science patent requests in Israel, or 1,523 patents, were from Israelis. In addition, some 1,000 US life science patents were granted in 2005 to Israelis, who submitted 2,827 requests there, which Cohn noted was out of proportion when compared to countries with much larger population sizes than Israel. "Switzerland, for example, with a population approximately three times that of Israel, received 1,214 and forwarded 2,222 patents for US approval last year," Cohn said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings